Aktienanalyse zu Heron Therapeutics Inc (HRTX)HRTXHeron Therapeutics Inc

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Heron Therapeutics Inc is not a good buy right now due to significant financial losses and a low current price of $0.2951, which is near its 52-week low of $0.26. The company reported a net loss of $5.49 million in Q2 2026, and its forward P/E ratio is high at 46.95, indicating that the stock may be overvalued at this time. Additionally, the RSI is at 39.15, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The main risk is the ongoing litigation regarding its CINVANTI patents, which has already led to a significant drop in stock price and could continue to impact future performance.

11 analysts cover HRTX: 11 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.